QQ客服 官方微博 反馈留言

	Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
	Chen, Nan; Qian, Jiaqi; Chen, Jianghua; Yu, Xueqing; Mei, Changlin; Hao, Chuanming; Jiang, Gengru; Lin, Hongli; Zhang, Xinzhou; Zuo, Li
刊名	NEPHROLOGY DIALYSIS TRANSPLANTATION
	2017
卷号	32期号:8
关键词	anemia in chronic kidney disease erythropoiesis erythropoietin hypoxia-inducible factor FG-4592
ISSN号	0931-0509
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3621667
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Chen, Nan,Qian, Jiaqi,Chen, Jianghua,et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION,2017,32(8).
APA	Chen, Nan.,Qian, Jiaqi.,Chen, Jianghua.,Yu, Xueqing.,Mei, Changlin.,...&Valone, Frank H..(2017).Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.NEPHROLOGY DIALYSIS TRANSPLANTATION,32(8).
MLA	Chen, Nan,et al."Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China".NEPHROLOGY DIALYSIS TRANSPLANTATION 32.8(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。